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The P-type ATPase affected in Wilson disease, ATP7B, is a key
liver protein required to regulate andmaintain copper homeostasis.
When hepatocytes are exposed to elevated copper levels, ATP7B
traffics from the trans-Golgi network toward the biliary canalicular
membrane to excrete excess copper into bile. The N-terminal
region of ATP7B contains six metal-binding sites (MBS), each with
the copper-binding motif MXCXXC. These sites are required for the
activity and copper-regulated intracellular redistribution of ATP7B.
Two proteins are known to interact with the ATP7B N-terminal
region: the copper chaperone ATOX1 that delivers copper to ATP7B,
and COMMD1 (MURR1) that is potentially involved in vesicular cop-
per sequestration. To identify additional proteins that interact with
ATP7B and hence are involved in copper homeostasis, a yeast two-
hybrid approach was employed to screen a human liver cDNA
library. The dynactin subunit p62 (dynactin 4; DCTN4) was identi-
fied as an interacting partner, and this interactionwas confirmed by
co-immunoprecipitation from mammalian cells. The dynactin
complex binds cargo, such as vesicles and organelles, to cytoplasmic
dynein for retrograde microtubule-mediated trafficking and could
feasibly be involved in the copper-regulated trafficking of ATP7B.
The ATP7B/p62 interaction required copper, the metal-binding
CXXCmotifs, and the region betweenMBS 4 andMBS 6 of ATP7B.
The p62 subunit did not interact with the related copper ATPase,
ATP7A. We propose that the ATP7B interaction with p62 is a key
component of the copper-induced trafficking pathway that delivers
ATP7B to subapical vesicles of hepatocytes for the removal of excess
copper into bile.
Copper is essential for the survival of all organisms because it is
required for a number of important copper-dependent enzymes (1).
Disruption of copper homeostasis leads to a number of diseases, includ-
ing the genetic disorders Wilson disease, Indian childhood cirrhosis,
and Menkes disease (2, 3).
The redox properties that make copper biologically useful as an
enzyme cofactor in numerous key cellular reactions (4) also render it
potentially toxic. This conflict between toxicity and essentiality requires
all organisms to have developed intricate and highly regulated copper
homeostatic mechanisms. The copper diseases occur when these sys-
tems fail, but in many cases our knowledge of the mechanisms is insuf-
ficient to understand disease pathogenesis.
In mammals, the overall copper status is mainly regulated by excre-
tion of excess copper into the bile. This process is disrupted in Wilson
disease, leading to massive accumulation of copper in the liver. Wilson
disease is caused bymutations inATP7B (reviewed in Ref. 5).Within the
hepatocyte, ATP7B is located at the trans-Golgi network (TGN)2 where
it transports copper to apoceruloplasmin (6).When intracellular copper
levels are in excess, it redistributes to a vesicular compartment located
toward the biliary canalicular membrane where excess copper is elimi-
nated from the cell into the bile either by exocytosis through fusion of
copper-loaded vesicles with the membrane (7, 8) or by effluxing copper
directly across the apical membrane (9, 10). When intracellular copper
levels are returned to normal ATP7B cycles back to the TGN (9).
There are sixmetal binding domainswithin theN-terminal regions of
ATP7B and the closely related copper ATPase defective in Menkes dis-
ease, ATP7A. Each domain is 70 amino acids in length, and each
contains oneMXCXXCmotif. The six repeatingMXCXXCmotifs bind
6 molar equivalents of copper via the conserved cysteines and are
involved in regulating the copper transport activity and copper-regu-
lated redistribution of the ATPases (10–13). Several studies have
revealed that a large portion of the N-terminal domain is not critical for
the overall transport activity and the intracellular redistribution of the
human copper-transporting ATPases (10, 14–18). For example, the
N-terminal region of ATP7B encompassing MBS 1–5 (amino acids
63–540) is not essential for copper-induced trafficking, with only one
MBS close to themembrane channel necessary and sufficient to support
trafficking (19). Hence the large N-terminal region of the ATPases that
contain the six MBS may have additional roles and potentially contains
other signals or motifs that could be important for the regulated traf-
ficking and targeting of ATP7A and ATP7B (17, 20–22).
Two proteins have been shown to interact with the N terminus of
ATP7B. The copper chaperone ATOX1 interacts with the N termini of
bothATP7A andATP7B in a copper-dependentmanner, and this inter-
action is essential for copper delivery to the secretory pathway (23–27).
The recently discovered protein COMMD1 (MURR1), which is absent
in Bedlington terriers suffering from copper toxicosis (28, 29), interacts
with the N terminus of ATP7B (29). The fact that COMMD1 interacts
with ATP7B but not with ATOX1 or ATP7A (29) is consistent with its
proposed role in copper excretion from the liver.
Despite their sequence and structural similarity and the presence of
six MBS within the N termini of the copper ATPases, clearly there are
sufficient differences in sequence and/or structure that confer specific-
ity of interactions with proteins such as COMMD1 and differences in
their trafficking pathways. The identification of a putative targeting sig-
nal in ATP7B that is not present or is different in ATP7A (20) suggests
that additional specific protein interactions are likely to impact on their
activity and/or trafficking.
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Only a limited number of proteins are known to be critical for copper
homeostasis, and little is known of the protein/protein interactions
required for this process. To better understand the function and regu-
lation of ATP7B in copper homeostasis, we have employed yeast two-
hybrid technology to identify additional proteins that interact with
ATP7B. The yeast two-hybrid system is a powerful and sensitive tool for
investigating protein interaction networks (30). Here we describe the
screening of a human liver cDNA library using the N-terminal region of
ATP7B as a bait to search for interacting partners.
This screen identified the protein p62 (dynactin 4;DCTN4), a subunit
of dynactin as potentially interacting with ATP7B. This interaction was
confirmed using yeast two-hybrid assays and co-immunoprecipitation
from mammalian cells. We showed that the p62 subunit of dynactin
interacts with the N terminus of ATP7B but not ATP7A. This interac-
tion was copper-dependent and required the CXXC motifs and the
region between MBS 4 and MBS 6. We propose that the ATP7B inter-
action with p62 is a key component of the copper-regulated trafficking
pathway that delivers ATP7B to subapical vesicles of hepatocytes for the
removal of excess copper into bile.
EXPERIMENTAL PROCEDURES
Bacteria, Yeast, andMammalianCell Strains—Escherichia coli strain
DH10B (F, mcrA, (mrr-hsdRMS-mcrBC), 80lacZM15, lacX74,
deoR, recA1, araD, (ara,leu)7697, galU, galK, rpsL, endA1, nupG) was
used for cloning, maintenance, and propagation of plasmids and was
cultured in Luria-Bertani (LB) medium (0.1% (w/v) tryptone (Difco),
0.05% (w/v) yeast extract (Difco), and 0.1% (w/v) NaCl) containing 100
g/ml ampicillin for plasmid selection. Saccharomyces cerevisiae strain
YGH1 (ura3-25 his3-200 ade2-101 lys-2,801 trp1-901 leu2-3 Canr
GAL4-542 gal80-538 LYS2::gal1uas-gal1tata-HIS3URA3::gal1-lacZ) (31)
and transformants thereof were maintained on standard yeast extract/
peptone/dextrose (YPD) (1% (w/v) yeast extract (Difco), 1% (w/v) tryp-
tone (Difco), 2% (w/v) glucose) solid or liquid medium (32), or the
appropriate synthetic complete drop out (SD) medium (Q-biogene) for
maintenance of plasmids, respectively. Copper-limited SDmediumwas
prepared using yeast nitrogen base without copper sulfate (Q-biogene)
and supplemented with the appropriate concentration of bathocu-
proine disulfonic acid (BCS) (Sigma). When copper supplementation
was required, CuSO4 was used.
Human skin fibroblast cells overexpressing ATP7A (A12-H9) or
ATP7B (WND-16) (33) were used for co-immunoprecipitation experi-
ments. The cell lines were maintained in Eagle’s basal medium (BME;
Thermo Trace) supplemented with 10% (w/v) fetal calf serum (Thermo
Trace), 2 mM L-glutamine, 0.2 mM proline, 20 mM HEPES, 0.2% (w/v)
sodium bicarbonate, and geneticin (400 g/ml) (Invitrogen). Cultures
were incubated at 37 °C in a 5% CO2-humidified incubator. Copper-
limitedmediumwas prepared by supplementing BMEwith 100MBCS
and 100 M D-penicillamine (Sigma).
Generation of Plasmid Constructs—To generate a bait construct that
encoded the entire N terminus of ATP7B, a 1971-bp fragment that
encoded amino acids 1–657was amplified by PCR using pCMB278 (19)
as a template, the forward primer 5-ccccatatgATGCCTGAGCAG-
GAGAGACAG-3 (hWND30) and the reverse primer 5-gggcagctgC-
GACGTGTCCTTTCTGAAGAAGGTGAC-3 (hWND8) (NdeI and
SalI restriction sites in lowercase boldface type). The resulting PCR
product was cloned into the NdeI/SalI restriction sites of the GAL4
DNA binding domain (BD) vector pAS2-1 (Clontech) to create plasmid
pAS2-1/ATP7B-N (pSLB10). A 1.8-kb fragment of ATP7A encoding
the N terminus from amino acid 1 to 600 was cloned as a BamHI/PstI
fragment from pCMB151 (24) into pAS2-1 to create pAS2-1/ATP7A-N
(pSLB34).
To create plasmid constructs that encoded mutated or deleted
ATP7B N termini as baits, PCR was carried out using the forward
primer hWND30, the reverse primer hWND8, and the following plas-
mids as templates (19): pCMB398, which encoded ATP7B with both
cysteines within the CXXCmotif of all six of the metal binding domains
mutated to serine (i.e. SXXS); pCMB404, which encoded ATP7B with
MBS 1–5 deleted leaving only MBS 6; and pCMB405, which encoded
ATP7B withMBS 4–6 deleted leavingMBS 1–3 intact. The PCR prod-
ucts were cloned into theNdeI/SalI restriction endonuclease sites of the
vector pAS2-1 (Clontech) to create the following plasmids: pAS2-1/
MBS1–6c/s (pSLB96); pAS2-1/MBS1–5del (pSLB97); and pAS2-1/
MBS4–6del (pSLB98), respectively. The liver cDNA library plasmid
isolated in the screen with ATP7B encoded the C-terminal 260 amino
acids of p62 fused in-frame with the GAL4 activation domain (AD) in
the vector pACT2 (Clontech) (pACT2/p62) (pSLB102) and was used in
-galactosidase assays with the various bait plasmids.
Yeast Two-hybrid Screening—The screening procedure employed
was a modification of the method described by Gietz and Wood (34).
S. cerevisiae YGH1 cells were sequentially transformed with pAS2-1/
ATP7B-N and a human liver cDNA library constructed in the pACT2
vector (Clontech) using the lithium acetate/salmon sperm carrier
DNA/polyethylene glycol method. Transformants were selected on SD
medium lacking tryptophan, leucine, and histidine supplementedwith 5
mM 3-amino-1,2,4-triazole (Sigma). To confirm the interactions, HIS
transformants were tested for lacZ expression using -galactosidase
colony-lift filter assays (64). True positives were verified by curing the
bait plasmid from the positive yeast clones, isolating the library plas-
mid(s) from Leu/Trp/(LacZ) auxotrophs, and re-transforming
library plasmids back into S. cerevisiae YGH1 either with the pAS2-1
vector alone or with pAS2-1/ATP7B-N to confirm the interactions.
Transformants were then re-assessed for -galactosidase activity. Plas-
mids that were confirmed to encode interacting proteins were trans-
formed into E. coli DH10B, and the cDNA inserts were subjected to
sequence analysis to determine the nature and identity of the encoded
protein.
To obtain a quantitative estimate of the extent of the interaction,
liquid -galactosidase assays that employed chlorophenol red--D-ga-
lactopyranoside (CPRG) (Sigma) as the substrate were carried out fol-
lowing the Clontech protocol (64). For each culture within a single
experiment, the -galactosidase activity of triplicate samples was meas-
ured. The values obtained represent -galactosidase activity calculated
in Miller units using the average value obtained from at least three
independent experiments S.D.
DNA Sequence Analysis—Sequencing of plasmid DNA was carried
out using ABI PRISM BigDye Terminator chemistry (Applied Biosys-
tems) with reactions analyzed on anApplied Biosystems 3730S capillary
sequencer apparatus at Micromon DNA Sequencing Facility, Monash
University (Melbourne, Australia). Sequence analysis and basic sequence
manipulationwereperformedusingSequencher (GeneCodesCorp.). Elec-
tronic data base searches were conducted using the BLASTN and
BLASTP algorithms on the NCBI website (www.ncbi.nlm.nih.gov).
Immunoblot Analysis of S. cerevisiae YGH1 Transformants—Total
protein extracts from S. cerevisiae YGH1 transformants were prepared
using the trichloroacetic acid extraction method as described in the
Yeast Protocols Handbook (64). Approximately 50 g of protein was
fractionated by SDS-PAGE (7.5 and 12.5% (v/v) acrylamide). Proteins
were transferred toHybond-Cnitrocellulosemembranes (Amersham
Biosciences) using a Trans-Blot semi-dry electrophoretic transfer appa-
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ratus (Bio-Rad) and detectedwith either sheep-derived, affinity-purified
NC36 anti-ATP7B antibody (diluted 1:500 (19)) or rabbit-derived anti-
bodies directed against the GAL4 DNA-BD (2 g/ml) (Sigma) or the
GAL4 AD (1 g/ml) (Sigma). Secondary antibodies used for detection
were a rabbit anti-goat IgG peroxidase conjugate (Sigma) and a goat
anti-rabbit IgG peroxidase conjugate (Chemicon), respectively. Protein
bands were detected after incubation in Lumi-Light Chemilumines-
cence blotting substrate (Roche Applied Science) and visualized using
the Luminescent Image Analyzer LAS-3000 (Raytest Isotopenmess-
geraete GmbH).
Co-immunoprecipitation and Immunoblot Analysis—Co-immuno-
precipitation of interacting proteins from mammalian cells was carried
out using the ProFoundTM Mammalian Co-immunoprecipitation Kit
(Pierce), and experiments were carried out and optimized using the
manufacturer’s instructions. Specifically, 200 g of the affinity-purified
anti-ATP7B antibody (NC36) (19), 200 g of the sheep-derived, affini-
ty-purified anti-ATP7A antibody (R17-BX) (35), and as a control the
sheep preimmune serum were covalently immobilized to the amine-
reactive antibody coupling gel. Menkes patient fibroblast cells that
expressed either ATP7A (A12-H9) or ATP7B (WND-16) (33) were
seeded in equivalent numbers and grown to confluence in 75-cm2 flasks
for 72 h either in the absence or presence of the copper chelators BCS
(100M) and D-penicillamine (100M). Cells were lysed, and the lysates
were applied to the gel according to the protocol provided. The protein
complexes were eluted in the elution buffer provided, boiled in sample
buffer with added dithiothreitol (20 mM final concentration), and frac-
tionated by SDS-PAGE (7.5% (v/v) and 12.5% (v/v) acrylamide). Proteins
were transferred to Hybond-C membrane (Amersham Biosciences)
using a Trans-Blot semi-dry electrophoretic transfer apparatus (Bio-Rad)
and analyzed by immunoblotting with either the NC36 anti-ATP7B anti-
body (diluted 1:500 (19)), the R17-BX anti-ATP7A antibody (diluted
1:1000) (35), or a goat-derived anti-human dynactin p62 polyclonal anti-
bodyN-17 (diluted1:1000; SantaCruzBiotechnology).The secondaryanti-
body used for detection was a rabbit anti-goat IgG peroxidase conjugate
FIGURE 1. Interaction of p62 with the N termi-
nus of ATP7B. A, schematic diagram showing the
full-length p62. The LIM domain is shown as a
hatched box, and the cysteine residues within the
LIM domain are indicated. The 260-amino acid
region of p62 encoded by the library plasmid
pACT2/p62 and that interacted with ATP7B-N is
shaded ingray. B,-galactosidase activity of S. cer-
evisiae YGH1 co-transformants. S. cerevisiae YGH1
was co-transformed with plasmids that encoded
p62 and either the wild-type ATP7B N terminus
(ATP7B-N) or the wild-type ATP7A N terminus
(ATP7A-N) as indicated. A control was included that
was co-transformed with pAS2-1/ATP7B-N and the
pACT2 AD vector. -Galactosidase activity of over-
night cultureswasmeasuredusingCPRGas the sub-
strate. The values shown represent -galactosidase
activity calculated inMiller units and using the aver-
age value obtained fromat least three independent
experiments S.D. C, expression of GAL4 DNA-BD
and AD fusion proteins. Panels show the GAL4
DNA-BD and AD fusion proteins (indicated above
each lane) that are expressed in each co-transfor-
mant as detected by immunoblot with affinity-puri-
fied GAL4DNA-BD and -AD antibodies (Ab) (Sigma),
respectively. The proteins in each lanewere derived
fromthesameco-transformants thatweretestedfor
-galactosidase activity shown directly above. The
position of protein molecular mass markers (Fer-
mentas) are shown on the left in kilodaltons (kDa).
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(Sigma). Protein bands were detected after incubation in Lumi-Light
chemiluminescence blotting substrate (RocheApplied Science) and visual-
ized using the Luminescent Image Analyzer LAS-3000 (Raytest Isotopen-
messgeraete GmbH).
RESULTS
Screening of a Human Liver cDNA Library for Binding Partners of the
ATP7BN-terminal Domain—To identify proteins that interact with the
ATP7B N-terminal domain in vivo, a yeast two-hybrid screen of a
human liver cDNA library was conducted using a bait protein that
included the ATP7BN terminus from amino acids 1 to 657. This region
includes all six metal binding domains to one amino acid before the first
transmembrane domain. The cDNA encoding the entire ATP7B N ter-
minus (ATP7B-N) was cloned into the vector pAS2-1 to create an in-
frame fusion with the GAL4 DNA-BD (pAS2-1/ATP7B-N). When
transformed into S. cerevisiaeYGH1 alone, or with theGAL4AD vector
(pACT2), this bait plasmid did not autoactivate expression of the HIS3
and lacZ reporter genes.
The pAS2-1/ATP7B-N plasmid and the liver cDNA library con-
structed in the pACT2 vector were sequentially transformed into S.
cerevisiae YGH1. Interaction of the bait protein with a library-encoded
protein was necessary to bring the GAL4 DNA-BD and -AD into close
proximity to activate transcription of the reporter genes. Approximately
3 106 transformants were screened for histidine prototrophy. Among
the 2,534 colonies isolated as HIS, 365 were also LacZ. The bait
plasmid was cured from positive transformants, and the library plasmid
DNA was isolated from each of these clones, transformed into E. coli,
isolated, and then retransformed into S. cerevisiae YGH1 that was pre-
transformed with either pAS2-1/ATP7B-N or pAS2-1 vector only.
Transformants were tested for -galactosidase activity. True positives
were those that were positive for -galactosidase activity when both
library and bait plasmids were present but negative for -galactosidase
activity when the library plasmid and pAS2-1 vector were present. Plas-
mid DNA from the true positive clones was isolated, sequenced, and
shown to encode a number of different cDNAs. A library plasmid that
encoded the dynactin subunit p62 was chosen for further detailed anal-
ysis based on the presence of many cysteine residues within its amino
acid sequence and the involvement of dynactin in protein trafficking.
This plasmid contained an insert of 3.1 kb, which included 778 bp of a
1380-bp open reading frame plus 2.3 kb of 3-untranslated sequence.
The open reading frame encoded amino acid 200 to the stop codon of
dynactin subunit p62 (260 amino acids) (Fig. 1A).
Dynactin Subunit p62 Interacts with the N Terminus of ATP7B but
Not ATP7A—To confirm the specificity of the ATP7B-N/p62 interac-
tion, S. cerevisiae YGH1 was co-transformed with pACT2/p62 and bait
plasmids constructed in pAS2-1 that encoded either ATP7B-N (pAS2-
1/ATP7B-N) or ATP7A-N (pAS2-1/ATP7A-N) fused in-frame to the
GAL4 DNA-BD. The negative control was a transformant that con-
tained pAS2-1/ATP7B-N and the empty library plasmid pACT2.
Co-transformants were analyzed for histidine prototrophy and -ga-
lactosidase activity, and the latter was measured qualitatively by the
colony-lift filter assay (data not shown) and semi-quantitatively using
a liquid culture assay (CPRG assay) (Fig. 1B).
These experiments demonstrated a significant and specific inter-
action between p62 and ATP7B-N (Fig. 1B). The negative control
showed that the positive -galactosidase result with ATP7B-N and
p62 did not arise from interaction with vector-derived proteins.
There was no interaction between p62 and the copper ATPase
ATP7A, which is closely related in structure and function to ATP7B
(Fig. 1B). Immunoblot analysis (Fig. 1C) of the co-transformants
confirmed that the appropriate fusion proteins were expressed so
that the negative -galactosidase results cannot be attributed to the
lack of protein expression.
Co-immunoprecipitation experiments were carried out to verify the
p62/ATP7B interaction in a mammalian cell environment. Using the
ProFoundTM Mammalian Co-immunoprecipitation Kit (Pierce), cell
lysates derived from a humanMenkes fibroblast cell line that expressed
either ATP7A (A12-H9) or ATP7B (WND-16) (33) were applied sepa-
rately to columns prepared with either immobilized ATP7A or ATP7B
primary antibodies, respectively, or preimmune serum. SDS-PAGE
analysis of the immune complexes eluted from the columns showed that
the anti-ATP7B antibody precipitated both ATP7B and endogenous
p62 from the lysate, whereas the preimmune serum did not precipitate
either protein (Fig. 2A). In contrast, the anti-ATP7A antibody precipi-
tatedATP7Abut not p62 from theATP7A-expressing cell line (Fig. 2B),
although endogenous p62 could be detected in the cell lysate. We con-
cluded that the interaction between ATP7B and dynactin subunit p62
represented a true and specific interaction in mammalian cells.
FIGURE 2. Co-immunoprecipitation of ATP7B and p62 from human fibroblast cell
lines. The fibroblast cell lines derived from a Menkes patient had been transfected pre-
viously to stably express either ATP7A (A12-H9) or ATP7B (WND-16) (33). Co-immuno-
precipitation (Co-IP) of interacting proteins was carried out using the ProFoundTMmam-
malian co-immunoprecipitation kit (Pierce). Cell lysates were added separately to
columns prepared with either immobilized ATP7B (NC36 (19)) or ATP7A (R17-BX (35))
affinity-purified primary antibodies (Ab) or sheep preimmune serum. Immune com-
plexeswere eluted in 50-l fractions, and samples (20l) were fractionated from the first
three elutions (Co-IP elution 1–3) on SDS-polyacrylamide gels. As controls for protein size
and expression, aliquots of cell lysates were prepared by adding 5l of sample buffer to
20l of lysate and loaded onto each gel. Following electrophoresis, proteinswere trans-
ferred to Hybond-C nitrocellulose membranes and probed as follows: A, panel i, NC36
(diluted 1:500 (19)); B, panel I, R17-BX (diluted 1:1000 (35)); or A, panel ii and B panel ii,
N-17, an anti-human dynactin p62 polyclonal antibody (diluted 1:1000). The sizes of
prestained protein molecular mass markers (Fermentas and Bio-Rad) are shown on the
right in kilodaltons (kDa). The positions of ATP7A, ATP7B, and p62 proteins are indicated
by arrows on the left.
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Dynactin p62 Interacts with the N Terminus of ATP7B in a Copper-
dependent Manner—To determine whether copper was required for
the interaction between p62 and the ATP7B N terminus, S. cerevisiae
YGH1 co-transformed with pAS2-1/ATP7B-N, and pACT2/p62 was
passaged for 48 h in copper-limitedmediumprepared by the addition of
the copper chelator, BCS, and the liquid -galactosidase assay was
repeated (Fig. 3A, panel i). The extent of the interaction was reduced
4-fold by 100 M BCS and was almost completely disrupted by the
addition of 500 M BCS. The addition of BCS did not affect the inter-
actions between the unrelated interacting pairs Bim and Bcl2 and Fos
and Jun (Fig. 3A, panel ii). This observation showed that the reduced
interaction between ATP7B-N and p62 in the presence of BCS was not
because of an effect of BCS on the activity of -galactosidase. The addi-
tion of 50 M CuSO4 to the BCS-supplemented medium restored the
ATP7B/p62 interaction to normal levels (Fig. 3B). There was maximal
interaction with the addition of 100MCuSO4. Note that protein levels
were not affected by the variations in the copper content of themedium,
so changes in the extent of the interaction were not a reflection of
copper-induced changes in protein expression (Fig. 3B).
The copper dependence of the ATP7B/p62 interaction was con-
firmed in mammalian cells by co-immunoprecipitation experiments.
To deplete cells of copper, equivalent numbers of WND-16 cells
were seeded into flasks and grown in the presence of 100M BCS and
100M D-penicillamine for 72 h. Using the ProFoundTMMammalian
Co-immunoprecipitation Kit (Pierce), cell lysates were prepared,
and samples containing equal amounts of total protein were applied
to a column prepared with immobilized NC36 ATP7B primary anti-
bodies. SDS-PAGE analysis of the immune complexes eluted from
the column showed that as before the NC36 antibody precipitated
both ATP7B and endogenous p62 from the cells grown in normal
medium (Fig. 3C, panel i). However, when cells were grown in cop-
per-depleted medium, there was a substantial reduction in the
amount of p62 that was co-precipitated with ATP7B (Fig. 3C, panel
ii). There was no difference in the amount of p62 or ATP7B protein
in each lysate indicating that the BCS treatment did not affect the
expression levels of these proteins. Hence, we concluded that the
reduction in the amount of p62 that was co-precipitated with ATP7B
was because of copper depletion, confirming that copper was
required for the ATP7B/p62 interaction in mammalian cells. Note
that concentrations of BCS between 50 and 500 M have been shown
previously to reverse or disrupt the copper-induced trafficking of the
ATPases (7, 8, 10, 36–38).
FIGURE 3. p62 interacts with the N terminus of
ATP7B in a copper-dependent manner. S. cerevi-
siae YGH1 cells were co-transformed with pAS2-1/
ATP7B-NandpACT2/p62 (A,panel I,andB). As a con-
trol, S. cerevisiae YGH1 cells were co-transformed
with yeast expression plasmids encoding either
GAL4 AD-Bim and GAL4 DNA-BD-Bcl2 fusions or
GAL4 AD-Fos and GAL4 DNA-BD-Jun fusions (A,
panel ii). Cultures of all co-transformants were pas-
saged for 48 h in copper-limited media supple-
mented with the indicated concentrations of the
copper chelator BCS (A), or in copper-limitedmedia
supplemented with 500 M BCS and the indicated
concentrations of CuSO4 (B). The extent of the inter-
action was then measured in three independent
experiments using the CPRG liquid -galactosidase
assay. Values shownrepresent themeanS.D. Pan-
els below the graph in B show immunoblots of the
GAL4 DNA-BD/ATP7B-N and GAL4 AD/p62 fusion
proteins that are expressed in each culture repre-
sented in the graph. Total protein extracts from the
untreated and treated cultures were subjected to
SDS-PAGE and immunoblotting with affinity-puri-
fied GAL4 AD (1 g/ml) (Sigma) and NC36 (diluted
1:500 (19)). An image of a portion of the Ponceau
Red-stained membrane is also shown to demon-
strate approximately equivalent protein loading in
each lane. C, the ATP7B/p62 interaction is depend-
ent on copper in mammalian cells. WND-16 fibro-
blast cells (33)weregrown for 72h in theabsenceor
presenceof100MBCSand100MD-penicillamine.
Co-immunoprecipitation of interacting proteins
was carried out using the ProFoundTM mammalian
co-immunoprecipitation kit (Pierce). Cell lysates
from treated and untreated cells were added sepa-
rately to a column prepared with immobilized
ATP7Baffinity-purifiedprimaryantibodies (19).Sam-
ples (20l) from the first two elutions (Co-IP elutions
1 and 2) were fractionated on SDS-polyacrylamide
gels. As controls for protein size and expression, ali-
quots of cell lysateswerepreparedbyadding5l of
sample buffer to 20 l of lysate and then loaded
onto each gel. Following electrophoresis, proteins
were transferred to Hybond-C nitrocellulose mem-
branes, andprobedas follows:panel I, NC36 (diluted
1:500 (19)), or panel ii,N-17, an anti-humandynactin
p62 polyclonal antibody (diluted 1:1000; Santa Cruz
Biotechnology). The sizes of prestained protein
molecular mass markers (Fermentas) are shown on
the right in kilodaltons (kDa). ThepositionsofATP7B
andp62proteins are indicated by arrowson the left.
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The Interaction between ATP7B and p62 Is Dependent Upon the
CXXC Motifs—To investigate the requirement for the CXXC motifs and
the involvement of the different MBS within the ATP7B N terminus in
the interaction with p62, bait proteins comprising the GAL4
DNA-BD fused to mutant ATP7B N-terminal regions were gener-
ated (Fig. 4A). A fusion construct was generated in which the cys-
teines in all six motifs were altered to serines (SXXS) (pAS2-1/
MBS1–6c/s). In addition, fusion constructs were generated that
contained only metal binding domain 6 (deleting amino acids
63–540) (pAS2-1/MBS1–5del) or metal binding domains 1–3 (delet-
ing amino acids 300–599) (pAS2-1/MBS4–6del). The fusion con-
structs were co-transformed into S. cerevisiae YGH1 with pACT2/
p62 and -galactosidase activity measured (Fig. 4B). The interaction
was negligible when all six CXXC motifs were mutated to SXXS,
clearly demonstrating a requirement for these motifs in the interac-
tion. There was no interaction between p62 and MBS4–6del and a
reduced but significant interaction between p62 and MBS1–5del.
These results indicated that the region between MBS 4 and 6 is
essential for the p62/ATP7B interaction. Again, immunoblot analy-
sis of co-transformants demonstrated expression of all fusion pro-
teins (Fig. 4C).
DISCUSSION
ATP7A and ATP7B are key proteins in copper homeostasis, and a
detailed understanding of the cellular constituents that regulate their activ-
ity and trafficking is required to complete the picture of how these mole-
cules function. Under basal copper levels, ATP7B has a steady state distri-
bution at the TGN (7, 14). In elevated copper, ATP7B traffics to large
multivesicular compartments within the cytoplasm of nonpolarized cells
(7, 14, 19, 39), and in polarized hepatocytes it redistributes to a subapical
vesicular compartment associatedwithapical vacuoles that are reminiscent
of bile canaliculi (7–10). Recent studies fromour group have provided sup-
port for a mechanism whereby the copper-loaded vesicles fuse with the
apical membrane to expel the copper into the bile (8).
FIGURE 4. The CXXC motifs and the MBS 4–6
region are required for the ATP7B/p62 interac-
tion. A, schematic illustration of the ATP7B mutant
proteins used in this study. The N-terminal metal
bindingdomains are shownas filled boxes. (i)MBS1–
6c/s, all of the cysteines in the CXXC metal-binding
motifs altered to serines (SXXS); (ii) MBS1–5del, the
first five metal binding domains deleted, leaving
only the first 63 amino acids and metal binding
domain6; (iii)MBS4–6del, thethreemostC-terminal
metal binding domains deleted, leaving only the
first 63aminoacids andmetal bindingdomains1–3.
B, GAL4 DNA-BD fusion constructs incorporating
these mutations were co-transformed with pACT2/
p62 into S. cerevisiae YGH1 cells. The extent of inter-
action was then measured in three independent
experiments using the CPRG liquid -galactosidase
assay. Values shownrepresent themeanS.D. Pan-
elsbelowthegraphshow immunoblotsof theGAL4
DNA-BD/ATP7B N-terminal mutation/deletion and
GAL4 AD/p62 fusion proteins that are expressed in
each culture represented in the graph. In the top
rightpanel theexpectedproteinbandsare indicated
by an asterisk. Protein extracts were subjected to
SDS-PAGE and immunoblotting with affinity-puri-
fied GAL4 AD (1 g/ml) (Sigma) and NC36 (diluted
1:500 (19)). The position of protein molecular mass
markers (Fermentas) are shownon the left in kilodal-
tons (kDa).
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Little is known of the precise route or the associated proteins required
for the traffickingofATP7B through the cell. TheN-terminal copper-bind-
ing motifs are present in all of the copper-transporting P-type ATPases,
albeit in varying numbers, and play a critical but incompletely defined role
in the transport and trafficking functions of both ATP7B and ATP7A (17,
19, 40, 41). Each metal binding domain binds copper (11–13, 22), but the
presence of all six domains is not necessary for the catalytic activity or the
copper-induced redistribution of the proteins (10, 14, 15, 17, 19). In partic-
ular, metal binding domain 6 appears to have an important role in copper
transport and trafficking (17, 19). The six metal binding domains are
between20 and60% identical to eachother, suggesting that theyhave func-
tions that are distinct from just binding copper and possibly mediated by
protein/protein interactions. In ATP7B, a putative vesicle targeting signal
existswithinmetal bindingdomain6andmayexert its effect through inter-
actions with the cell sortingmachinery (20). This signal is not present or is
different inATP7A supporting the notion that different proteins and inter-
actions are likely to be involved in the different trafficking pathways of the
ATPases in the cell. So far, two proteins are known to interact with the
ATP7B N terminus. ATOX1 interacts with the N termini of both ATP7A
andATP7B in a copper-dependentmanner to allow the delivery of copper
to the ATPases (23–27). COMMD1, possibly involved in vesicular copper
sequestration, also interacts with the N-terminal region of ATP7B but not
ATP7A (29). Given the importance of the N-terminal region in both traf-
ficking and copper transport, we undertook a yeast two-hybrid screening
approach to identify additional interacting partners.
A human liver cDNA library was screened with the N terminus of
ATP7B. One of the proteins confirmed to interact with ATP7B-N in
yeast, dynactin subunit p62, was chosen for further analysis. Based on
the proposed role of dynactin in tethering cargo to the retrograde
microtubule motor protein dynein, the subunit p62 represented a can-
didate likely to be implicated in the copper-induced trafficking of
ATP7B from the TGN to the subapical vesicular compartments. Yeast
two-hybrid experiments showed that p62 interacted specifically with
the N terminus of ATP7B but not with that of the related ATPase
ATP7A. The lack of interaction between p62 and the ATP7A N termi-
nus and also between p62 and ATOX1 (data not shown) confirmed that
the interactionwithATP7Bwas specific. Co-immunoprecipitation con-
firmed the interaction in mammalian cells, while the inability of the
ATP7A antibody to co-immunoprecipitate ATP7A and p62 further
confirmed the specificity of the interaction.
Dynactin is a multisubunit complex that binds both to microtubules
(42) and to the retrograde microtubule motor protein dynein (43, 44).
Cytoplasmic dynein is targeted to a variety of subcellular structures and
requires the activity of dynactin for all of its known cellular functions
that include organelle and vesicle transport (reviewed in Ref. 45).
Although the specific function of the interaction between dynein and
dynactin is unknown, there is evidence that dynactin enhances the
microtubule binding capabilities and motility of cytoplasmic dynein
(46) and links dynein to its cellular cargo (47). The 11 different dynactin
subunits range in size from 22 to 150 kDa, and formany, their individual
roles within the dynactin complex have been well characterized
(reviewed in Ref. 48).
Dynactin subunit p62 is a ubiquitously expressed 53-kDa protein,
with a punctate cytoplasmic and centrosomal subcellular localization,
similar to other dynactin subunits (49). The function of the p62 subunit
is not fully understood, but its absence does not significantly impact
dynactin stability (50). The most prominent feature of p62 is its highly
conserved cysteine-rich domain (amino acids 30–114) in the N-termi-
nal region in which 8 of the 11 cysteines in this region form a LIM
domain (49, 51, 52). The LIM domain is a zinc binding protein/protein
interaction domain (reviewed in Ref. 53), and it has been proposed that
p62 uses this region to bind to other dynactin subunits or tomembrane-
associated phospholipids (48, 49). There are five additional cysteine
residues in the C-terminal half of p62, two of which form a CXXCmotif
that is highly conserved among homologs from Drosophila melano-
gaster, Caenorhabditis elegans, mouse, and Neurospora and hence is
likely to be functionally important. The clone isolated from the liver
cDNA library in this study encoded theC-terminal region of p62 (amino
acids 200-stop (460)) that does not include the LIM domain but con-
tains the five additional cysteine residues that may also be implicated in
the copper dependence of the interaction between p62 and ATP7B.
Hepatocytes establish a horizontal polarity axis with a horizontal
microtubule arrangement (54). The microtubules within these polar-
ized cells are organized from sites near the apical surface and are ori-
ented with their minus ends emanating at the apical plasma membrane
and their plus ends attached to or near the basolateral surface (55, 56).
Hepatocytes use predominantly an indirect biosynthetic route to target
their biliary canalicular membrane proteins initially to the basolateral
membrane and associated endosomes, followed by transcytosis to the
apical lumen (57). Transport to the apical domain by both direct and
indirect routes involves microtubule-based motility. Previous studies
have shown that the microtubule inhibitor nocodazole prevented cop-
per-induced trafficking of ATP7B (9), and biliary copper excretion was
inhibited by treating rats with colchicine, an inhibitor of microtubule
polymerization (58). These observations suggest that microtubules are
involved in the copper-induced trafficking of ATP7B to the apical sur-
face of hepatocytes. Because dynein is a minus-end directed microtu-
bule motor protein (59) and because ATP7B traffics toward the apical
surface of polarized hepatocytes in elevated copper (9, 10), we propose
that dynein/dynactin, through interaction between p62 and ATP7B,
mediates microtubule-based copper-induced trafficking of ATP7B to
the apical membrane via the indirect transcytotic route. Microtubules
are not required for the delivery of proteins to the basal membrane (60,
61). This observation is consistent with our finding that ATP7A, which
in elevated copper traffics to the basolateral membrane of polarized
epithelial cells (62, 63), did not interact with p62.
The interaction between ATP7B-N and p62 was dependent on cop-
per as is the interaction between the ATPases and ATOX1 (23–27).
This copper dependence further implicates p62 and dynactin as key
components in the copper-responsive trafficking pathway of ATP7B.
The interaction between the ATP7B N terminus and p62 also required
the conserved CXXC motifs of ATP7B, because mutation of the cys-
teines in all six metal binding domains disrupted the interaction. In the
full-length ATP7B, this mutation abolished the copper-regulated redis-
tribution of ATP7B from the TGN to subapical vesicular compartments
(19) and the copper transport activity of ATP7B (17). Together these
results suggest that the ATP7B/p62 interaction requires the copper-
bound MBS. Importantly, although the CXXC motifs were critical for
the ATP7B/p62 interaction, because ATP7A andATOX1 did not inter-
act with p62, it is likely that the ATP7B/p62 interaction involves
sequence and/or structural elements in addition to the CXXC motifs.
Experiments using the ATP7B-N deletion mutants localized the
region important for ATP7B/p62 interaction to between MBS 4 and 6.
There was significant but reduced interaction between p62 and the
ATP7B-NMBS1–5del mutant. The full-length protein with this muta-
tion could still traffic as wild-type ATP7B (19) and transport copper
(17). In contrast, theMBS4–6del protein did not interact with p62, and
the full-length protein with this mutation could not traffic in response
to copper (19) nor transport copper (17). These data link the transport
and trafficking function of ATP7B to its ability to interact with p62. A
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recent study by Guo et al. (10) showed that the N-terminal 63 amino
acids of ATP7B play a role in the copper-regulated trafficking of ATP7B
and could potentially contain a targeting signal that directs the protein
from the basolateral membrane to the apical surface. Although all of the
wild-type and mutant constructs used in this study contained these
N-terminal 63 amino acids (19), the relative contributions of this region
and the ATP7B/p62 interaction in the copper-regulated trafficking of
ATP7B in hepatocytes needs to be further investigated.
Our data clearly demonstrate a requirement for copper, functional
CXXC motifs, and the region between MBS 4 and 6 for the interaction
between ATP7B and p62 to occur. Based on our current understanding
of the role of dynactin in the cell, we propose that this interaction is
important for the copper-regulated trafficking of ATP7B to the apical
surface of polarized hepatocytes.
It was proposed previously that as copper is bound to the N-terminal
MBS of the ATPases, there is a conformational change, and a specific
targeting signal within the N terminus is exposed, which enables the
protein to traffic through interaction with components of the cell sort-
ing machinery (17, 20–22). Using our data in combination with that of
Guo et al. (10), we propose a model for copper-induced conformational
changes and subsequent microtubule-mediated apical trafficking of
ATP7B in response to elevated copper concentrations. When intracel-
lular copper levels are low, theMBS of ATP7B are not entirely saturated
with copper, and the protein is predominantly located at the TGN.
When copper levels become elevated, more copper is delivered to
ATP7B and all available MBS become loaded with copper. The N-ter-
minal region, replete with copper, undergoes a conformational change,
and the protein traffics via a default pathway to the basolateral mem-
brane. Here p62 interacts with the N terminus of ATP7B, in a mecha-
nism that may involve the N-terminal 63 amino acids, to target the
copper-bound protein for microtubule-mediated trafficking toward the
biliary canalicularmembrane. Thismodel assumes indirect transcytosis
of ATP7B to the apical membrane via the basolateral membrane. This
model would also explain why p62 did not interact with the similar
copper transporter ATP7A. TheN termini of ATP7A and ATP7B differ
significantly in the region between MBS 4 and 6 and within the region
prior to MBS 1, with this latter region in ATP7A comprising only 10
amino acids, whereas ATP7B has 63 (10). Copper-loadedATP7Awould
traffic to the basolateral membrane but would not be recognized by p62
for microtubule-mediated apical trafficking.
The identification of dynactin subunit p62 as an interacting partner of
ATP7B represents an important discovery of a key cellular component
implicated in the copper-regulated trafficking pathway of ATP7B. The
discovery of this interaction and its dependence on copper will not only
be instrumental in deciphering other signals and interactions that are
integral to this pathway but is already providing insight into the molec-
ular basis for the mechanistic differences between the trafficking path-
ways of ATP7A and ATP7B. This study is significant in furthering our
understanding of the molecular mechanisms and pathways that lead to
the maintenance of copper homeostasis and that will provide new tar-
gets for diagnosis and therapy of copper-related diseases.
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